Navigation Links
Taking Chemo Drug Continuously Delayed Lung Cancer's Return
Date:6/5/2011

By Amanda Gardner
HealthDay Reporter

SUNDAY, June 5 (HealthDay News) -- While most patients with advanced lung cancer only take four courses of two chemotherapy drugs and then stop until recurrence occurs, continuing treatment with one of those drugs may delay return of the deadly disease, new research suggests.

The results are preliminary, but Spanish scientists report that staying on Alimta (pemextrexed) delayed recurrence of the disease.

"This is the first trial with what looks like a positive outcome where you continue the same treatment," said Dr. Neal Ready, a professor of medicine at the Duke Cancer Institute in Durham, N.C. "All the other positive trials in the past switched chemotherapy regimens, so this is a true 'maintenance' approach" in that doctors maintained the patients on the same drug.

Although overall survival data is not yet in, "if it all bears out and that looks good, this would influence medical oncologists to continue treatment after the standard combination of two chemotherapies at the same time," Ready said.

The findings, which were presented Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago, was funded by Lilly, which makes Alimta.

In this study, almost 1,000 patients with advanced nonsquamous non-small cell lung cancer were given a typical four courses of Alimta and cisplatin. The 539 patients who saw their disease stabilize were then randomly chosen to receive Alimta or a placebo.

Participants taking Alimta lived an average of 4.1 months without a disease recurrence compared to 2.8 months in the placebo group.

"There was a decrease of 38 percent in the risk of progression, which we believe is clinically significant and may support the use of this in a clinical context," said study author Dr. Luis Paz-Ares, chair of oncology at Seville University Hospital in Seville, Spain, who spoke at a Sunday news conference.

Side effects were about the same as those seen in previous trials of Alimta, with the only significant increases in problems being fatigue, anemia and low white blood cell count.

But in all those cases, the incidence was lower than 5 percent, Paz-Ares said.

According to Lilly, the cost of Alimta varies depending up on the patient's size but is about $4,000 per cycle wholesale.

When asked if oncologists would be likely to prescribe this medication given the possibly prohibitive cost, Dr. Mark G. Kris, moderator of the press conference and chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York City, said that he thought they would, at least for patients in which the drug worked and was tolerable.

"The benefit would be worth the spending for people who get a benefit," he said.

Ready believes that doctors' willingness to use the drug will ultimately depend on seeing the overall survival results which, said Paz-Ares, "may be available in the near future."

The American Cancer Society reports that lung cancer is the leading cause of cancer death among both men and women, killing more people than colon, breast, and prostate cancers combined. The chance that a man will develop lung cancer is about one in 13; for a woman, about one in 16. While the estimates include both smokers and non-smokers, for smokers the risk is much higher.

Research presented at medical meetings should be considered preliminary until it is published in a peer-reviewed journal.

More information

The U.S. National Cancer Institute has more on lung cancer.

SOURCES: Neal Ready, M.D., Ph.D., professor, medicine, Duke Cancer Institute, Durham, N.C.; June 5, 2011, news conference with Luis Paz-Ares, M.D., Ph.D., chair, oncology, Seville University Hospital, Seville, Spain; Mark G. Kris, M.D., chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York City


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kids Taking ADHD Drugs at Low Risk for Heart Problems: Study
2. No increase in severe cardiovascular events for children, adolescents taking ADHD medications
3. Taking additional selenium will not reduce cancer risk
4. Women Taking Calcium Supplements May Risk Heart Health, Researchers Say
5. Taking Responsibility for Own Health Often Not Enough
6. Leukemia Patients Taking Gleevec Achieve Normal Death Rate
7. Taking tamoxifen to prevent breast cancer can save lives and money
8. Follow-Up Deemed Lacking for People Taking Opioids
9. Taking Short Breaks From Sitting May Help Waistline and Heart
10. PSA test better predicts cancer in men taking prostate-shrinking drug
11. Patients may not have to stop taking anti-platelets for some surgeries
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Taking Chemo Drug Continuously Delayed Lung Cancer's Return
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: